

REMARKS

Claims 14 and 21 are amended herein.
Claims 31-34 are cancelled.
Claims 35 and 36 are new.

Claim Rejections- 35 U.S.C. § 112

The pending claims were rejected under 35 U.S.C. § 112 for failing to particularly point out and distinctly claim the subject matter which the applicant regards as the invention. Specifically, the independent claims 14 and 21 failed to define R⁴. Applicants apologize for this oversight, and the newly amended claims 14 and 21 define R⁴ as defined in the specification and in the original claims. Thus, applicants believe that the statute is now satisfied.

Objection


It is Applicants understanding Z in the amended claims was broader than the elected subject matter. The claims have been amended such that Z is "benzothiophenyl or substituted benzothiophenyl." Applicants believe that this is what the Office Action has required. However, if this is not satisfactory, Applicants request that the Examiner contact the agent by phone so that the claims can be corrected to conform to this requirement. Applicants also request that Examiner contact the agent by phone if Z has been narrowed more than the restriction requires.

Since claim 31 has been deleted, the objection due to the typographical error is now moot.

Claims 35 and 36 are supported in the specification (pp. 11-12), and the non-elected compounds have been removed.

Please use Deposit Account 01-0885 for any fees or credits related to this response.

Respectfully submitted,



Brent A. Johnson
Registration No. 51,851
Agent of Record
Telephone: 714/246-4348
Facsimile: 714/246-4249

Date: June 3, 2005

Please send all inquires to:
Brent A. Johnson (T2-7H)
Allergan, Inc.
2525 Dupont Drive
Irvine, CA 92612